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PAntiplatelet Therapy
A Double-Blind, Randomized Study on
Prevention and Existence of a Rebound Phenomenon
of Platelets After Cessation of Clopidogrel Treatment
Dirk Sibbing, MD, Julia Stegherr, MS, Siegmund Braun, MD, Julinda Mehilli, MD,
Stefanie Schulz, MD, Melchior Seyfarth, MD, Adnan Kastrati, MD, Nicolas von Beckerath, MD,
Albert Schömig, MD
Munich, Germany
Objectives The goal of this study was to assess whether a platelet rebound exists and whether it can be attenuated by clo-
pidogrel tapering.
Background Clinical studies have reported a clustering of thrombotic events after stopping clopidogrel treatment. The hypoth-
esis of a rebound phenomenon of platelets has been declared causative, but its existence has never been con-
firmed. Tapering of clopidogrel over a certain period of time before stopping the drug completely might provide a
way to attenuate this supposed phenomenon.
Methods Patients (n  69) receiving clopidogrel treatment due to prior drug-eluting stent placement and planning to stop
clopidogrel were recruited in a double-blind, randomized trial. Patients were randomized to either receive a pre-
specified tapering regimen (tapering group; n  35) for 4 weeks with complete discontinuation of clopidogrel
thereafter or continue a daily clopidogrel intake for 4 more weeks with abrupt discontinuation afterwards (off
group; n  34). Platelet aggregation (PA) was assessed with light transmission aggregometry (LTA) and multiple
electrode aggregometry (MEA) simultaneously at study inclusion and at weeks 2 to 8 after randomization. The
primary end point was the highest value of adenosine diphosphate–induced PA measured with LTA in the weeks
after complete cessation of clopidogrel in both groups.
Results The highest values of adenosine diphosphate–induced PA after complete cessation of clopidogrel were similar
between both groups (p  0.21 with LTA, and p  0.55 with MEA).
Conclusions Tapering of clopidogrel does not result in lower PA values after clopidogrel withdrawal. The course of PA values
after clopidogrel cessation provides no evidence for the existence of a rebound phenomenon of platelets.
(J Am Coll Cardiol 2010;55:558–65) © 2010 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.09.038a
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tn coronary artery disease (CAD) patients with drug-eluting
tent (DES) placement, a dual antiplatelet regimen of
spirin and clopidogrel is the mainstay treatment strategy to
revent thrombosis of the treated vessels and subsequent
schemic events (1–3). Whereas a lifelong treatment with
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ccepted September 14, 2009.spirin is recommended for CAD patients with prior stent
lacement, current guidelines recommend antiplatelet treat-
ent with clopidogrel for a time-period of 6 to 12 months
fter DES implantation (1–3). In daily clinical practice,
atients who are scheduled to stop clopidogrel therapy do it
bruptly.
Recently, different clinical studies have demonstrated a
lustering of thrombotic events after discontinuation of long-
erm clopidogrel treatment (4,5). Ho et al. (5) reported, in both
edically treated and percutaneous coronary intervention
PCI)-treated patients with an acute coronary syndrome, a
lustering of all-cause mortality and acute myocardial infarc-
ion in the very first weeks after stopping treatment with
lopidogrel. The hypothesis of a rebound phenomenon of
lood platelets has been declared causative, but its existence in
he context of clopidogrel withdrawal has never been addressed
y specifically designed studies. In vitro, such a rebound
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February 9, 2010:558–65 Tapering Clopidogrel and Platelet Reboundhenomenon of platelets after clopidogrel cessation might
ecome manifest in a significant peaking of adenosine diphos-
hate (ADP)-induced platelet aggregation values soon after
topping clopidogrel treatment completely. Because different
tudies have demonstrated that insufficient suppression of
latelet reactivity to ADP is associated with an increased risk of
hrombotic events after coronary stent placement (6–9), the
bserved clustering of adverse events reported in clinical studies
ight be related to an intermittent status of platelet hyper-
eactivity or so-called platelet rebound with very high ADP-
nduced platelet aggregation levels. A tapering of clopidogrel
reatment over a certain period of time before stopping the
ntake of the drug completely might provide a beneficial
reatment strategy to attenuate this supposed rebound phe-
omenon of platelets (5). The goal of this study was to assess
hether a rebound phenomenon exists after stopping long-
erm clopidogrel treatment and whether it can be attenuated by
clopidogrel-tapering regimen.
ethods
tudy population. Between March 2008 and October
008 patients were enrolled in this double-blind, random-
zed study at the Deutsches Herzzentrum München (Tech-
ische Universität München, Munich, Germany). The
AD patients on long-term (6 months) dual antiplatelet
reatment with aspirin (100 mg twice/day) and clopidogrel
75 mg/day) after DES placement were eligible for this
tudy if they were scheduled to stop clopidogrel treatment.
Patients were enrolled after a follow-up angiography and
re-angiography loading with 600 mg of clopidogrel, which
s a routine follow-up procedure for patients with prior PCI
n our clinic. Only patients who did not need a (re-)
ntervention were included. This is because a new interven-
ion would have required an extension of dual antiplatelet
herapy duration. Exclusion criteria were age18 years and age
80 years, angiographic lesions requiring re-intervention,
alignancies or other comorbid conditions that might result
n protocol noncompliance, a history of stent thrombosis
ST), prior treatment with glycoprotein IIb/IIIa inhibitors
uring the 10 days before study inclusion, pregnancy, and
elevant hematologic deviations (hemoglobin 100 g/l,
latelet count 100  109 cells/l or platelet count 600 
09 cells/l). The present study complies with the Declara-
ion of Helsinki and was approved by the institutional ethics
ommittee. All patients gave written informed consent
efore entering the study.
tudy design. This study was a prospective, randomized,
nd double-blind platelet function study. Patients with
he plan to stop clopidogrel treatment were eligible for
tudy inclusion and for randomization. Patients were
andomized to either receive a pre-specified tapering
egimen (tapering group) over a pre-defined time period
f 28 days with complete cessation of clopidogrel there-
fter or continue treatment with 75 mg clopidogrel daily
or a further 28 days with abrupt discontinuation after- lards (off group). Sealed enve-
opes that contained the treat-
ent code and the study
edication were used for the
andomization process and
ere provided by the pharmacy
f the Deutsches Herzzentrum
ünchen, Munich, Germany.
he envelopes were numbered
equentially on the basis of a
omputer-generated random-
zation list and contained a
edication blister with pre-
ared medication in 28 num-
ered compartments for 28
ays. For the off group, each
ompartment contained 1 tablet
f 75 mg clopidogrel (verum).
or the tapering group, a pre-
pecified tapering regimen was
sed consisting of 75-mg clopi-
ogrel tablets (verum) or placebo tablets. The tapering
egimen for the 28 days (4 weeks) was as follows (1 
erum, 0  placebo): week 1: 1/0/1/0/1/0/1, week 2:
/0/1/0/0/1/0, week 3: 0/1/0/0/0/1/0, and week 4: 0/0/
/0/0/0/1. Double-blinding was achieved by using simi-
arly appearing tablets for clopidogrel and for placebo in
he 2 treatment groups. Thereby, operators and patients
ere completely blinded to the treatment regimen. All
atients received the treatment regimen to which they
ere randomized. The randomized treatment was started
he day after the control angiography before discharge of
atients. From this time point onward, all patients were
nder treatment with 100 mg aspirin (twice/day) and the
ssigned study medication (once/day) for 28 days. After
8 days the study medication was finished, and aspirin
as continued indefinitely.
Study enrollment, randomization, and follow-up of pa-
ients for the present trial was completely independent of
he currently ongoing double-blind and randomized ISAR-
AUTION (Abrupt Versus Tapered Interruption of
hronic Clopidogrel Therapy After DES Implantation)
rial (NCT00640679).
lood sampling and follow-up of patients. For all pa-
ients, peripheral venous blood samples for platelet function
esting were drawn at all time points throughout the study
n a fasting state through a short venous catheter inserted
nto a forearm vein. The first tube drawn was labeled as a
iscard and was not used for platelet function testing.
latelet function was measured with 2 different methods
imultaneously—in platelet-rich plasma (PRP) with light
ransmission aggregometry (LTA) and in whole blood with
ultiple electrode platelet aggregometry (MEA). For plate-
et function testing with LTA, blood was placed in 5.0-ml
lastic tubes containing the anticoagulant citrate. For plate-
Abbreviations
and Acronyms
ADP  adenosine
diphosphate
AU  aggregation units
CAD  coronary artery
disease
DES  drug-eluting stent(s)
LTA  light transmission
aggregometry
MEA  multiple electrode
platelet aggregometry
PCI  percutaneous
coronary intervention
PPP  platelet-poor plasma
PRP  platelet-rich plasma
ST  stent thrombosis
TRAP  thrombin-receptor
activating peptideet function testing with MEA, blood was placed in 4.0-ml
p

s
b
s
s
s
p
T
r
p
m
p
e
a
L
a
p
w
p
p
s
e
c
c
a
h
w
a
fi
M
g
M
b
w
w
t
r
M
t
E
(
A
u
m
f
E
p

i
t
p
p
w
(
8
p
v
p
3
w
a
c
I
a
p
t
a
p
o
S
t
p
s
u
p
g
M
w
p
f
s
c
o
b
d
R
A
3
p
a
t
p
s
i
p
o
P
o
p
a
n
g
t
o
g
t
d
560 Sibbing et al. JACC Vol. 55, No. 6, 2010
Tapering Clopidogrel and Platelet Rebound February 9, 2010:558–65lastic tubes containing the anticoagulant lepirudin (25
g/ml, r-hirudin, Dynabyte, Munich, Germany). Blood
amples were kept at room temperature for at least 30 min
efore platelet function testing.
Blood for platelet function testing was taken at pre-
pecified time points during the study period. The first
ample was taken in the hospital directly after study inclu-
ion after the control coronary angiography. Further sam-
les were taken at outpatient follow-up visits of the patients.
hese samples were taken at weeks 2, 3, and 4 after
andomization, which corresponds to the time period when
atients were under the randomized study treatment regi-
en, and further on at weeks 5, 6, 7, and 8 during the time
eriod without any intake of clopidogrel in all patients. The
mpty medication blister was collected from all patients to
ssess compliance with the study protocol.
TA. LTA was used to assess agonist-induced platelet
ggregation in citrated PRP with the platelet aggregation
rofiler (PAP 8) aggregometer (Moelab, Berlin, Germany)
ith a constant stirring rate of 1,200 rpm at 37°C. The final
latelet count was adjusted to 250  109/l with autologous
latelet-poor plasma (PPP). The PRP (0% light transmis-
ion) and PPP (100% light transmission) served as refer-
nces. As agonists, ADP (Moelab) was used in different
oncentrations (1.25, 2.5, 5, and 20 mol/l) as well as
ollagen (0.19 mg/ml) (Moelab) and thrombin-receptor
ctivating peptide (TRAP) (25 mol/l) (Sigma, Deisen-
ofen, Germany). After baseline adjustment, the agonist
as added and aggregation was recorded for 6 min. The
nalyzed parameter was maximal aggregation (%) within the
rst 6 min after addition of the agonist.
EA. Aggregation in whole blood was assessed on a new
eneration impedance aggregometer with MEA on the
ultiplate analyzer (Dynabyte). Details of this method have
een reported previously (8,10). In brief, after dilution (1:2
ith 0.9% sodium chloride solution) of hirudin-anticoagulated
hole blood and stirring for 3 min in the test cuvettes at 37°C,
he agonist was added and aggregation was continuously
ecorded for 6 min. Platelet aggregation was measured by
EA in response to 6.4 mol/l ADP (ADPtest), in response
o 6.4mol/l ADP in the presence of 9.4 nmol/l prostaglandin
1 (ADPtest HS), in response to 32 mol/l TRAP-6
TRAPtest), and in response to 3.2g/ml collagen (COLtest).
ggregation measured with MEA is quantified as aggregation
nits (AU) and area under the curve of AU (AU  min). All
aterial used, including the different agonists, was obtained
rom the manufacturer (Dynabyte).
nd points and sample size calculation. The primary end
oint of the study was the highest level of maximal ADP (5
mol/l)-induced platelet aggregation measured with LTA
n the time period after complete cessation of clopidogrel
reatment (weeks 5 to 8). Sample size calculation for the
resent study was based on the assumption that the mean
eak levels of ADP (5 mol/l)-induced platelet aggregation
ere 80% in the off group versus 65% in the tapering groupabsolute difference in means of 15%). Choosing a power of m0% and a 2-sided -level of 0.05, we calculated that 29
atients in each group were needed (NQuery advisor,
ersion 7.0, Statistical Solutions, Cork, Ireland). To com-
ensate for a loss to follow-up, we aimed for the inclusion of
4 patients/group. The secondary end point of the study
as the highest level of ADP (6.4 mol/l)-induced platelet
ggregation with MEA measured in the time period after
omplete cessation of clopidogrel treatment (weeks 5 to 8).
n addition, we recorded the entire time course of platelet
ggregation values in both groups in order to detect a
ossible rebound phenomenon of platelets and we also
ested for significant differences of agonist-induced platelet
ggregation values between the 2 study groups for each time
oint separately in the time period after complete cessation
f clopidogrel treatment (weeks 5 to 8).
tatistical analysis. Variables of patients’ baseline charac-
eristics are presented as mean  SD or counts and
ercentages. Categorical variables were compared with chi-
quare test, and continuous variables were compared with
npaired t test. The Wilcoxon test was used to compare the
revious clopidogrel treatment interval between both
roups. Platelet function data obtained with LTA and
EA are presented as mean  SEM and were compared
ith unpaired t test for between group comparisons and
aired t test for in group comparisons. Analyses were per-
ormed with the software package S-PLUS version 4.5 (In-
ightful Corp., Seattle, Washington). The p values0.05 were
onsidered statistically significant. No corrections in the level
f significance for multiple comparisons were undertaken,
ecause comparisons at the different time points and for the
ifferent agonists were considered as exploratory.
esults
total of 69 patients were enrolled in this study, of whom
5 patients were randomized to the tapering group and 34
atients were randomized to the off group. Baseline char-
cteristics and concomitant medical treatment of the pa-
ients according to the study treatment regimen applied are
resented in Table 1. No significant differences were ob-
erved between the 2 groups. The controlling of the med-
cation blister demonstrated full compliance with the study
rotocol in all patients. No ischemic or bleeding events
ccurred during the study period.
latelet aggregation with LTA. For the primary end point
f the study, the highest value of ADP (5 mol/l)-induced
latelet aggregation (in percentage) measured with LTA
fter complete cessation of clopidogrel during weeks 5 to 8,
o significant differences were observed between the 2 study
roups (73.0 2.5% in the off group vs. 69.3 1.5% in the
apering group; p  0.21). Figure 1 shows the time course
f ADP-induced platelet aggregation values for the 2 study
roups in the weeks after randomization. For all concentra-
ions of ADP used (1.25 to 20 mol/l), no significant
ifferences were observed for between group comparisons of
ean values (off group vs. tapering group) for the distinct
t
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February 9, 2010:558–65 Tapering Clopidogrel and Platelet Reboundime points after complete cessation of clopidogrel at weeks
, 6, 7, and 8 (p  0.39 for 1.25 mol/l ADP, p  0.40 for
.5 mol/l ADP, p  0.35 for 5 mol/l ADP, p  0.54 for
0 mol/l ADP). Figure 2 shows the course of TRAP- and
ollagen-induced platelet aggregation values for the 2 study
roups in the weeks after randomization. For both agonists
sed, no significant differences were observed for between
roup comparisons of mean values (off group vs. tapering
roup) for the distinct time points after complete cessation
f clopidogrel at weeks 5, 6, 7, and 8 (p  0.15 for TRAP,
nd p  0.31 for collagen).
Due to administration of a 600-mg loading dose of
lopidogrel on top of a clopidogrel maintenance treatment
efore the coronary angiography, platelet aggregation values
ere significantly lower at week 0 after randomization
ompared with week 2 after randomization (p  0.01 for
aseline CharacteristicsTable 1 Baseline Characteristics
Variable
Off Group
(n  34)
Tapering Group
(n  35)
p
Value
Age (yrs) 67.7 9.5 66.2 7.6 0.48
Women 5 (14.7) 9 (25.7) 0.26
Body mass index (kg/m2) 26.1 3.0 27.7 4.7 0.09
Diabetes mellitus 6 (17.6) 6 (17.1) 0.96
Active smokers 3 (8.8) 5 (14.3) 0.48
Arterial hypertension 32 (94.1) 33 (94.3) 0.98
Hypercholesterolemia 25 (74.0) 24 (69.0) 0.65
Family history of CAD 12 (35.0) 16 (46.0) 0.38
Multivessel disease 30 (88.2) 26 (74.3) 0.14
Previous myocardial infarction 13 (38.0) 11 (31.0) 0.55
Previous PCI 34 (100.0) 35 (100.0) —
Previous bypass surgery 5 (14.7) 1 (3.0) 0.08
Previous clopidogrel intake
(months)*
12 (7–19) 7 (7–14) 0.34
Platelet count,  109 cells/l 215.4 50.3 218.5 49.2 0.80
Hemoglobin level (g/dl) 14.4 1.2 14.2 1.5 0.41
Comedication
Aspirin 34 (100.0) 35 (100.0) —
Beta-blocker 29 (85.3) 32 (91.4) 0.43
ACE inhibitors 22 (65.0) 24 (69.0) 0.73
Statins 31 (91.2) 31 (88.6) 0.72
Calcium-channel blockers 6 (17.6) 2 (5.7) 0.12
Proton pump inhibitors 9 (26.0) 11 (31.0) 0.65
Characteristics of antecedent PCI
Clinical presentation 0.88
Stable angina 21 (61.8) 21 (60.0)
Acute coronary syndrome 13 (38.2) 14 (40.0)
Drug-eluting stent implantation 0.87
Sirolimus-eluting stent 17 (50.0) 20 (57.1)
Everolimus-eluting stent 11 (32.3) 11 (31.4)
Paclitaxel-eluting stent 4 (11.8) 3 (8.6)
Zotarolimus-eluting stent 2 (5.9) 1 (2.9)
ata presented are mean  SD or n (%) unless otherwise indicated. Characteristics of antecedent
ercutaneous coronary intervention (PCI) (clinical presentation, drug-eluting stent implantation)
enote characteristics at the time point of the initial PCI in the time period before study inclusion.
Previous clopidogrel intake (in months) corresponds to the time interval between starting
lopidogrel treatment and study inclusion and is expressed as median (interquartile range).
ACE  angiotensin-converting enzyme; CAD  coronary artery disease.oth LTA and MEA measurements). elatelet aggregation with MEA. For the secondary end
oint of the study, the highest value of ADP (6.4 mol/l)-
nduced platelet aggregation (in AU  min) measured with
EA after complete cessation of clopidogrel during weeks
to 8, no significant differences were observed between the
study groups (925 43 AUmin in the off group vs. 890
9 AU  min in the tapering group; p  0.55). Figure 3
hows the course of agonist-induced platelet aggregation
alues for the 2 study groups in the weeks after randomiza-
ion. For all agonists used, no significant differences were
bserved for between group comparisons of mean values (off
roup vs. tapering group) for the distinct time points after
omplete cessation of clopidogrel at weeks 5, 6, 7, and 8
p  0.32 for ADP, p  0.18 for ADP in the presence of
rostaglandin E1, p  0.48 for TRAP-6, p  0.06 for
ollagen).
iscussion
ere we report the first double-blind and randomized trial
n the prevention and existence of a rebound phenomenon
f platelets after cessation of clopidogrel treatment. The first
ain result of the study is that a tapering of clopidogrel
reatment as compared with abrupt cessation of the drug
oes not result in significantly lower platelet aggregation
alues in the time period after complete cessation of
lopidogrel treatment. The second main result of the study
s that the time course of platelet aggregation values—
egardless of the device, the agonist, or the agonist concen-
ration used—after clopidogrel cessation provides no evi-
ence for the existence of a rebound phenomenon of
latelets after discontinuing clopidogrel.
Results of this study were obtained concordantly with 2
ifferent devices used for platelet function testing. Specifi-
ally, we measured platelet aggregation in PRP with LTA,
hich is still considered to be the gold standard in this
etting, but also in whole blood with MEA on the Multi-
late analyzer (Dynabyte) (8,10). For both LTA and MEA,
n association of post-treatment platelet reactivity in re-
ponse to ADP and the occurrence of ischemic events has
een demonstrated in prospective studies (6,8,11). There-
ore major results of our study are strengthened by the fact
hat we found no evidence for the existence of a rebound
henomenon and for a possible benefit of clopidogrel
apering with any of the 2 different devices used. Additional
TA measurements were performed with low concentra-
ions of ADP (1.25 and 2.5 mol/l) to avoid extensive
ggregation after complete cessation of clopidogrel and that
ould have masked a possible rebound phenomenon. These
easurements did not show any evidence for platelet
ebound after abrupt cessation of clopidogrel therapy. Be-
ides P2Y12 pathway stimulation with ADP, we imple-
ented the use of collagen and TRAP as agonists for
latelet aggregation measurements. For all agonists used
nd regardless of the concentration that was used for ADP,
vidence for the existence of a rebound phenomenon or for
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Tapering Clopidogrel and Platelet Rebound February 9, 2010:558–65possible benefit of tapering clopidogrel was not provided
y any of our investigations.
In the present study we investigated platelet function
arameters over a total time span of 8 weeks, including
easurements over a period of 4 weeks after complete
essation of clopidogrel. It is highly unlikely that a rebound
henomenon of platelets would occur later than 4 weeks
fter complete cessation of the drug, for several reasons.
aving left the bone marrow, platelets survive for approx-
mately 8 to 10 days on average, and approximately 10% to
5% of platelets are exchanged/day (12,13). In line with
his, it was reported in different studies that a full recovery
f platelet function after discontinuation of clopidogrel is
bserved within 5 to 7 days after complete withdrawal of the
rug (13,14). If a rebound phenomenon of platelets would
ndeed exist, it would be likely to occur at that time point,
hen the entire platelet pool is exchanged after clopidogrel
ithdrawal, with platelets in the circulation being com-
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of adenosine diphosphate (ADP). Platelet function data are presented as mean va
domization. The p value was nonsignificant for between-group comparisons at weeletely uninhibited and in an assumed hyper-reactive state. chis time point might be estimated—taking into account
he platelet life span and the time of platelet function
ecovery after clopidogrel withdrawal—at week 2 after
omplete cessation of the drug, which corresponds to week
after randomization in the off group of patients in our
tudy setting. For all platelet function parameters studied
ere, however, we did not observe a peaking of platelet
ggregation values at week 6 or even thereafter (Figs. 1 to 3).
Limited data are available on proaggregatory or proin-
ammatory effects after withdrawal of thienopyridine treat-
ent. Serebruany et al. (15) described a patient in whom
elatively high markers of platelet activation and aggregation
ere measured after discontinuation of prasugrel due to
oncompliance. In addition, Angiolillo et al. (16) observed
roaggregatory and proinflammatory effects in diabetic pa-
ients after clopidogrel withdrawal. None of these studies,
owever, was designed to assess a possible rebound phe-
omenon of platelets or a possible benefit of tapering
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February 9, 2010:558–65 Tapering Clopidogrel and Platelet ReboundA clustering of thrombotic events has previously been
eported for different antithrombotic agents in the time
ourse after their cessation, including aspirin (17), unfrac-
ionated heparin (18,19), and clopidogrel (5,20,21). For
lopidogrel, however, evidence for the existence of a re-
ound phenomenon of platelets after drug cessation mainly
tems from clinical studies investigating the occurrence of
linical events in relation to stopping clopidogrel treatment.
vailable clinical studies, however, have provided conflict-
ng results in this context. In a retrospective cohort study of
,137 acute coronary syndrome patients from Ho et al. (5),
clustering of death or myocardial infarction was observed
n the very first weeks after stopping clopidogrel in both
edically treated and PCI-treated patients. In line with
his, other studies and case report collections in patients
ith prior stent placement have also reported on a clustering
f ischemic events, including ST early after cessation of
hienopyridine treatment (20–22). Whereas possible evi-
ence for the existence of a rebound phenomenon of
latelets is provided by these studies, results of other studies
o not fit into this assumption. In an observational study
ncluding 10,778 patients with sirolimus-eluting stent im-
lantation, discontinuation of thienopyridine treatment
lone was not associated with an excess of ST in any of the
ime intervals studied (23). In a prospective observational
ohort study including 3,021 patients with prior DES
lacement, opposing results were found for a possible
ssociation of adverse events and discontinuation of thieno-
yridine therapy (4). In this cohort study, discontinuation of
hienopyridine treatment was only found to be a strong and
ndependent predictor (p  0.001) for the occurrence of ST
ithin 6 months after coronary stenting. Thienopyridine
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after randomization. The p value was nonsignificant for between-group comparisonessation after 6 months of stenting did not predict the vccurrence of ST (p  0.92). Recently, similar results were
eported by Lemesle et al. (24), who compared patients (n
,254) who stopped their clopidogrel treatment within the
rst 6 months, between 6 and 12 months, and after 12
onths after coronary stent placement. This study demon-
trated that clopidogrel cessation was only associated with
n increased short-term risk of adverse events when clopi-
ogrel was stopped within the first 6 months after PCI.
esults of the latter studies (4,24) challenge the existence of
rebound phenomenon of platelets after clopidogrel cessa-
ion, which would be expected to be manifest at any time
oint after stopping the drug, and further strengthen the
ypothesis that the clustering of thrombotic events after
ES implantation and cessation of clopidogrel is mainly
elated to the extent of re-endothelialization and stent
overage.
linical implications. Although tapering of clopidogrel
reatment does not result in significantly lower absolute
alues of ADP-induced platelet aggregation in the weeks
fter stopping clopidogrel, a possible clinical benefit of
apering clopidogrel in CAD patients with prior stent
lacement cannot be excluded from the results of the
resent study. It could be hypothesized that, apart from the
aximal values of platelet aggregation observed, a more
radual increase of platelet aggregation values achieved by a
lopidogrel-tapering regimen is beneficial for the reduction
f thrombotic events. In fact, we observed a relatively rapid
ncrease of platelet aggregation values in the off group of
atients in our study. Whether this rapid increase might be
isadvantageous in case of stopping clopidogrel treatment
emains uncertain. The clinical safety and efficacy of abrupt
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Tapering Clopidogrel and Platelet Rebound February 9, 2010:558–65fter DES implantation will be addressed in a separate and
ndependent study, the ISAR-CAUTION trial.
tudy limitations. In this study extensive assessment of
gonist-induced platelet aggregation was performed with
ifferent ADP concentrations and additional agonists with 2
ifferent methods. We did not assess surface expression of
ctivation-dependent platelet membrane receptors. How-
ver, ADP-induced platelet aggregation has been by far the
ost broadly used parameter to link platelet function to the
isk of ischemic events after PCI. Only patients with stable
oronary artery disease and concomitant aspirin treatment
ere included in our study. Therefore it cannot be excluded
hat a rebound phenomenon of platelets after clopidogrel
essation might occur in clinically unstable patients or in
atients without any concomitant oral antiplatelet treat-
ent. Here, we have evaluated a potentially clinically
elevant issue, that of platelet function response after
lopidogrel discontinuation in patients receiving chronic
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hould be considered as “rebound” or simply as recovery
f platelet function after 2 approaches of clopidogrel
iscontinuation.
onclusions
apering of clopidogrel does not result in lower platelet
ggregation values after complete cessation of clopidogrel
reatment. The course of platelet aggregation values after
lopidogrel cessation provides no evidence for the existence
f a rebound phenomenon of platelets after discontinuation
f clopidogrel.
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